Titan Pharma (TTNP) Explores Strategic Alternatives

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Titan has engaged Maxim Group LLC as its exclusive financial advisor to assist in this process.

Potential strategic alternatives that may be explored or evaluated as part of this process include an acquisition, merger, reverse merger, other business combination, sales of assets, licensing or other strategic transactions involving the Company. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive terms. Titan does not expect to disclose developments with respect to this process unless and until the evaluation of strategic alternatives has been completed or the board of directors has concluded that disclosure is appropriate or legally required.

You May Also Be Interested In

• Z Squared outlines AI power strategy and Paradox Data acquisition
• Diginex signs amended deal to acquire Resulticks for $1.05B
• XTEND positions itself for U.S. drone tariff market shift